Trials / Unknown
UnknownNCT05046847
A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3811 Tablets in Patients With Advanced Malignant Tumors
Phase I Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3811 Tablets in Patients With Advanced Malignant Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
TQB3811 tablet is a second-generation tropomyosin receptor kinase (TRK) inhibitor that selectively inhibits the kinase activity of TRKA, TRKB, and TRKC, and also selectively inhibits the kinase activity of TRKA, TRKB, and TRKC that produce secondary drug-resistant mutations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB3811 | TQB3811 is a second-generation TrkA inhibitor. |
Timeline
- Start date
- 2021-11-30
- Primary completion
- 2022-10-01
- Completion
- 2022-12-01
- First posted
- 2021-09-16
- Last updated
- 2021-12-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05046847. Inclusion in this directory is not an endorsement.